Free Trial Information
BioCentury | Aug 10, 2019
Product Development

Payers’ view of reimbursement when gene therapy isn’t enough

...IX gene therapies are in Phase III testing for hemophilia B as well: fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Mar 2, 2019
Product Development

Roche broadens its BD scope

...authorities. Novartis has rights to Luxturna outside the U.S. Spark’s most advanced clinical candidate is SPK-9001...
...which is in Phase III testing for hemophilia B. Pfizer Inc. has worldwide rights to SPK-9001...
Read More
BioCentury | Mar 1, 2019
Company News

Spark gives Roche beachhead in gene therapy

...takeout of AveXis Inc. in April 2018. Spark's next most advanced program is fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Feb 25, 2019
Company News

Spark gives Roche beachhead in gene therapy

...takeout of AveXis Inc. in April 2018. Spark's next most advanced program is fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Feb 13, 2019
Clinical News

uniQure gene therapy leads to sustained Factor IX activity in Phase IIb study

...least one other gene therapy is in Phase III testing for hemophilia B: fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Feb 8, 2019
Clinical News

uniQure gets bump on latest hemophilia readout

...least one other gene therapy is in Phase III testing for hemophilia B: fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Nov 16, 2018
Clinical News

uniQure hemophilia B gene therapy leads to Factor IX activity level of 31% of normal

...at least two other gene therapies in the clinic for hemophilia B -- fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Nov 15, 2018
Clinical News

uniQure gains on Factor IX activity data for hemophilia B gene therapy

...at least two other gene therapies in the clinic for hemophilia B -- fidanacogene elaparvovec (SPK-9001...
Read More
BioCentury | Jul 20, 2018
Clinical News

Pfizer begins Phase III lead-in study of hemophilia B candidate

...Pfizer Inc. (NYSE:PFE) began an open-label Phase III lead-in study evaluating fidanacogene elaparvovec (formerly SPK-FIX, SPK-9001...
...Inc. (NASDAQ:ONCE), Philadelphia, Pa. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Fidanacogene elaparvovec (formerly SPK-FIX, SPK-9001...
...consumption and number of bleeding events Status: Phase III started Milestone: NA Jaime De Leon PF-06838435, SPK-9001, SPK-FIX Pfizer...
Read More
BioCentury | Dec 15, 2017
Clinical News

Spark reports Phase I/II bleeding rate data for SPK-9001 in hemophilia B

...10 hemophilia B patients showed that a single IV dose of gene therapy candidate SPK-9001 (SPK-FIX...
...of 11.1 events per year at baseline to 0.4 events per year after treatment (p=0.02). SPK-9001...
...Spark Therapeutics Inc. (NASDAQ:ONCE), Philadelphia, Pa. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: SPK-9001 (SPK-FIX...
Read More
Items per page:
1 - 10 of 38